Early Adjuvant Chemotherapy Dose Reductions Correlate With Poorer Survival in Breast Cancer

Rachel Narozniak, MA
Published: Wednesday, Oct 30, 2019
breast cancer
Early dose reductions in a common adjuvant chemotherapy regimen were associated with inferior survival outcomes in a retrospective study of women with intermediate- to high-risk breast cancer (N = 1302) that evaluated chemo-therapy total cumulative dose (TCD) and early versus late dose reductions.

≤.001), and have fewer comorbidities (84.5% vs 72.8%) than those treated with the lower TCD.

Table. Five-Year Survival Rates By Dosing Cohorts

Table. Five-Year Survival Rates By Dosing Cohorts
Veitch Z, Khan OF, Tilley D, et al. Impact of cumulative chemother-apy dose on survival with adjuvant FEC-D chemotherapy for breast cancer. J Natl Compr Canc Netw. 2019;17(8):957-967. doi:10.6004/jnccn.2019.7286.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication